GlassScriptPhysician profile
Matthew C Blazek
NPI 1053317248
$1,561.49
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,561.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $244.30 | 2019 | |
| Novo Nordisk INC | $220.44 | 2019 | |
| Pfizer INC. | $161.26 | 2019 | |
| Glaxosmithkline, LLC. | $156.44 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $127.72 | 2019 | |
| Lilly USA, LLC | $127.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.47 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.84 | 2019 | |
| Shire North American Group INC | $46.94 | 2019 | |
| Sanofi-Aventis U.S. LLC | $42.02 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.45 | 2019 | |
| Allergan, INC. | $34.19 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.57 | 2019 | |
| Abbvie INC. | $27.96 | 2019 | |
| Amarin Pharma, INC. | $26.95 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $26.82 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.01 | 2019 | |
| Astellas Pharma US INC | $23.48 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.38 | 2019 | |
| Merck Sharp & Dohme LLC | $17.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.77 | 2019 | |
| Hikma Pharmaceuticals USA | $12.84 | 2019 | |
| Mannkind Corporation | $12.65 | 2019 | |
| Bioventus LLC | $11.40 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Blazek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.